Comparison of Simvastatin and Metformin in Treatment of Polycystic Ovary Syndrome: Prospective Randomized Trial
Comparison of Simvastatin and Metformin in Treatment of Polycystic Ovary Syndrome: Prospective Randomized Trial
复制标题
DOI：
10.1210/jc.2009-1674
复制
发表时间：
2009-12-01
影响因子：
5.8
通讯作者：
Duleba, Antoni J.
中科院分区：
文献类型：
--
作者：
Banaszewska, Beata;Pawelczyk, Leszek;Duleba, Antoni J.
内容：多囊卵巢综合征（PCOS）的特征是卵巢功能障碍和高雄激素血症;它还与心血管风险增加有关，例如血脂异常和内皮功能障碍。Metastatin，最近，他汀类药物已被证明可以改善内分泌和代谢方面的PCOS.Objective：本研究的目的是比较辛伐他汀和二甲双胍对PCOS.Design的影响：在一项前瞻性试验中，PCOS妇女（n = 136）被随机分配到辛伐他汀（S），二甲双胍（M），或辛伐他汀加二甲双胍（SM）组。在基线和3个月后进行评估。设置：本研究在一个学术医疗中心进行。主要结果：血清总睾酮的变化是measured.Results：本研究完成了113名受试者。所有组的总睾酮均显著降低，S、M和SM组分别降低17.1%、13.6%和15.1%。在所有组中也观察到体重指数、C反应蛋白和可溶性血管细胞粘附分子-1显著降低。DHEAS仅在S组中显著下降。没有一种治疗与LH或FSH的显著变化相关。总胆固醇和低密度脂蛋白胆固醇显着下降，只有在S和SM groups.Conclusions：辛伐他汀治疗是上级单独二甲双胍，而辛伐他汀和二甲双胍的组合是没有显着上级单独辛伐他汀。（临床内分泌代谢杂志94：4938-4945，2009）
Context: Polycystic ovary syndrome (PCOS) is characterized by ovarian dysfunction and hyperandrogenism; it is also associated with increased cardiovascular risks such as adverse lipid profile and endothelial dysfunction. Metformin and, more recently, statins have been shown to improve endocrine and metabolic aspects of PCOS.Objective: The aim of the study was to compare effects of simvastatin and metformin on PCOS.Design: In a prospective trial, women with PCOS (n = 136) were randomized to simvastatin (S), metformin (M), or simvastatin plus metformin (SM) groups. Evaluations were performed at baseline and after 3 months.Setting: The study was conducted at an academic medical center.Primary Outcome: The change of serum total testosterone was measured.Results: The study was completed by 113 subjects. Total testosterone decreased significantly and comparably in all groups: by 17.1, 13.6, and 15.1%, respectively, in the S, M, and SM groups. Significant decreases were also observed in all groups with respect to body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. DHEAS declined significantly only in the S group. None of the treatments were associated with significant changes in LH or FSH. Total cholesterol and low-density lipoprotein cholesterol significantly declined only in S and SM groups.Conclusions: Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone. (J Clin Endocrinol Metab 94: 4938-4945, 2009)